Status:
UNKNOWN
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
Lead Sponsor:
Sheba Medical Center
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
We propose to develop a personalized pharmacogenetic approach including the major genetic markers of warfarin (coumadin) dosing and patients' age and weight. The known genetic determinants include sev...
Detailed Description
Objective: To date, most warfarin-related pharmacogenetic studies are cross-sectional or retrospective association studies. There have been no prospective studies designed to evaluate the impact of g...
Eligibility Criteria
Inclusion
- patients starting warfarin therapy
Exclusion
- pregnant women
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00654823
Start Date
June 1 2008
End Date
June 1 2011
Last Update
April 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Clinical Pharmacology
Tel Litwinsky, Israel, 52621